CN101679522A - 肿瘤微环境的调控 - Google Patents

肿瘤微环境的调控 Download PDF

Info

Publication number
CN101679522A
CN101679522A CN200880017793A CN200880017793A CN101679522A CN 101679522 A CN101679522 A CN 101679522A CN 200880017793 A CN200880017793 A CN 200880017793A CN 200880017793 A CN200880017793 A CN 200880017793A CN 101679522 A CN101679522 A CN 101679522A
Authority
CN
China
Prior art keywords
antibody
cell
blood
cells
malignant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880017793A
Other languages
English (en)
Chinese (zh)
Inventor
K·哈利哈兰
S·赫
S·坦格里
T·云
A·莫里纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idec Pharmaceuticals Corp
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of CN101679522A publication Critical patent/CN101679522A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880017793A 2007-03-28 2008-03-28 肿瘤微环境的调控 Pending CN101679522A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90864507P 2007-03-28 2007-03-28
US60/908,645 2007-03-28
PCT/US2008/058744 WO2008119071A1 (en) 2007-03-28 2008-03-28 Modulation of tumor microenvironment

Publications (1)

Publication Number Publication Date
CN101679522A true CN101679522A (zh) 2010-03-24

Family

ID=39485176

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880017793A Pending CN101679522A (zh) 2007-03-28 2008-03-28 肿瘤微环境的调控

Country Status (8)

Country Link
US (1) US20100203010A1 (https=)
EP (1) EP2139923A1 (https=)
JP (1) JP2010522772A (https=)
CN (1) CN101679522A (https=)
AU (1) AU2008230724A1 (https=)
BR (1) BRPI0809386A2 (https=)
CA (1) CA2682027A1 (https=)
WO (1) WO2008119071A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6014799B2 (ja) * 2010-07-20 2016-10-26 Ｌｉｎｆｏｐｓ有限会社 解析によるミクロな腫瘍免疫挙動の顕微鏡的把握方法
EP3147297B1 (en) * 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
US9567642B2 (en) 2012-02-02 2017-02-14 Massachusetts Institute Of Technology Methods and products related to targeted cancer therapy
US8961957B2 (en) 2012-06-27 2015-02-24 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
US9907819B2 (en) 2012-06-27 2018-03-06 Kenichiro Hasumi Therapy and methods of introducing immature dendritic cells and/or cytotoxic T lymphocyte and anti-TNF antibody for treatment of tumors
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
WO2015077532A1 (en) * 2013-11-21 2015-05-28 Hasumi International Research Foundation Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti-tnf antibody for treatment of tumors
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CA2942245C (en) * 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3215163B1 (en) * 2014-11-06 2021-03-10 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
US20160206717A1 (en) * 2015-01-16 2016-07-21 Batu Biologics, Inc. Stimulation of immunity to endothelial cells, endothelial-like cells, and intratumor vascular channels derived from tumor tissue
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506915A (ja) * 1995-06-07 1999-06-22 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃｄ８０およびｃｄ８６発現細胞に対して特異的なイムノトキシン
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
WO2001089567A1 (en) * 2000-05-22 2001-11-29 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies

Also Published As

Publication number Publication date
JP2010522772A (ja) 2010-07-08
CA2682027A1 (en) 2008-10-02
WO2008119071A1 (en) 2008-10-02
US20100203010A1 (en) 2010-08-12
AU2008230724A1 (en) 2008-10-02
AU2008230724A8 (en) 2009-11-26
BRPI0809386A2 (pt) 2014-09-09
EP2139923A1 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
CN101679522A (zh) 肿瘤微环境的调控
CN107530423B (zh) 用抗lap单克隆抗体治疗癌症
JP6611709B2 (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
RU2155190C2 (ru) Иммуностимуляторные моноклональные антитела
JP2022513778A (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
US20220047632A1 (en) Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell
JP2020528744A (ja) がん細胞を標的化するキメラ抗原受容体のための方法および組成物
CN111683677A (zh) 使用抗体-药物缀合物调节免疫应答
TWI883067B (zh) 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
JP2021531813A (ja) キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用
TW202227506A (zh) 藉由靶向NTPDase3增強抗腫瘤免疫反應之方法及組合物
US20250074981A1 (en) Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
JP2022553643A (ja) 細胞傷害性ｔ細胞耐性腫瘍を治療するための組成物および方法
WO2019007075A1 (zh) 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用
KR20230008751A (ko) 피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
TWI922280B (zh) 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
US20250171533A1 (en) Kir3dl3 inhibitors and immune cell activating agents
KR20250060146A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
HK40109251A (zh) 用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法
KR20240099363A (ko) 항-pd-1 항체와 항-cd30 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
HK40126667A (zh) 嵌合抗原和t细胞受体及使用的方法
KR20230107478A (ko) 치료 항체 및 그의 용도
WO2019221574A1 (ko) 골수유래억제세포 관련 질환의 예방 및 치료 용도
HK40014553A (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100324